Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Atezolizumab,"Subcutaneous formulation, NSCLC, and all other IV atezolizumab indications",Atezolizumab (Tecentriq),Community and Hospital,
